COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AS A SECOND-LINE THERAPY IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CHINA

被引：0
|
作者：
Xiao, D. [1 ]
Zhu, S. [1 ]
Sun, W. [2 ]
Xuan, J. [3 ]
机构：
[1] Shanghai Centennial Sci Co Ltd, Shanghai, Peoples R China
[2] Bayer Healthcare Co Ltd, Beijing, Peoples R China
[3] Sun Yat Sen Univ, Guangzhou, Guangdong, Peoples R China
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.831
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIH31
引用
收藏
页码：S187 / S188
页数：2
相关论文
共 50 条
  • [41] Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study
    Qiao, Liang
    He, Wei
    Wang, Guoying
    Chen, Huanwei
    Huang, Fuxi
    Zhang, Bo
    Qiu, Yuxiong
    Liu, Shaoru
    Huang, Zhenkun
    Yuan, Yichuan
    Qiu, Jiliang
    Yuan, Yunfei
    Li, Binkui
    CANCER MEDICINE, 2024, 13 (09):
  • [42] Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China
    Huahua Zhang
    Yandong Zhang
    Chaonan Huang
    Jiangfeng Wang
    Clinical Drug Investigation, 2021, 41 : 569 - 577
  • [43] Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China
    Zhang, Huahua
    Zhang, Yandong
    Huang, Chaonan
    Wang, Jiangfeng
    CLINICAL DRUG INVESTIGATION, 2021, 41 (06) : 569 - 577
  • [44] Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States
    Hu, Jia
    Ye, Zhuomiao
    Xu, Zhe
    Hao, Zhinan
    Wang, Yongjun
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [45] Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    Cai, Hongfu
    Xu, Baohua
    Li, Na
    Zheng, Bin
    Zheng, Zhiwei
    Liu, Maobai
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [46] Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
    Zheng, Zhiwei
    Lin, Yuxuan
    Cai, Hongfu
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [47] Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia
    Whalen, John
    Stillman, Ipek
    Ambavane, Apoorva
    Felber, Eugene
    Makenbaeva, Dinara
    Bolinder, Bjorn
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (05) : 445 - 461
  • [48] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH LENVATINIB FOR THE TREATMENT OF ADVANCED SECOND-LINE ENDOMETRIAL CANCER
    Yfantopoulos, N.
    Gountas, I
    Skroumpelos, A.
    Theiakos, K.
    Economou, O.
    Karokis, A.
    VALUE IN HEALTH, 2024, 27 (12) : S113 - S113
  • [49] A study of cadonilimab combined with regorafenib as second-line or later therapy in patients with advanced hepatocellular carcinoma (aHCC)
    Qi, Qi
    Liu, Yang
    Li, Rentao
    Liu, Yayue
    Zhang, Xihao
    Lu, Wei
    Li, Huikai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain
    G. Villa
    L. J. Hernández-Pastor
    M. Guix
    J. Lavernia
    M. Cuesta
    Clinical and Translational Oncology, 2015, 17 : 24 - 33
12345